Activities and Contributions BREAKING
NEWS
Read more
Webinar 8 - Multiple Sclerosis (MS) LATEST
VIDEO
More Videos
Frontiers in Medicine On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective Marco Viceconti, Maria Tome, Wilhelmus Dartee, Igor Knezevic, Sabina Hernandez Penna, Claudia Mazzà, Brian Caulfield, Judith Garcia-Aymerich, Clemens Becker, Walter Maetzler, Thierry Troosters, Basil Sharrack, Giorgio Davico, Solange Corriol-Rohou, Lynn Rochester and the Mobilise-D Consortium Other publications LATEST
PUBLICATION
SOCIAL MEDIA Mobilise-D joins panel discussion about connected health devices BREAKING
NEWS
Read more
Webinar 8 - Multiple Sclerosis (MS) LATEST
VIDEO
More Videos
Frontiers in Medicine On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective Marco Viceconti, Maria Tome, Wilhelmus Dartee, Igor Knezevic, Sabina Hernandez Penna, Claudia Mazzà, Brian Caulfield, Judith Garcia-Aymerich, Clemens Becker, Walter Maetzler, Thierry Troosters, Basil Sharrack, Giorgio Davico, Solange Corriol-Rohou, Lynn Rochester and the Mobilise-D Consortium Other publications LATEST
PUBLICATION
SOCIAL MEDIA Koen Van den Brande BREAKING
NEWS
Read more
Webinar 8 - Multiple Sclerosis (MS) LATEST
VIDEO
More Videos
Frontiers in Medicine On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective Marco Viceconti, Maria Tome, Wilhelmus Dartee, Igor Knezevic, Sabina Hernandez Penna, Claudia Mazzà, Brian Caulfield, Judith Garcia-Aymerich, Clemens Becker, Walter Maetzler, Thierry Troosters, Basil Sharrack, Giorgio Davico, Solange Corriol-Rohou, Lynn Rochester and the Mobilise-D Consortium Other publications LATEST
PUBLICATION
SOCIAL MEDIA Mobilise-D Webinar – Up and Go: Planning & Conducting the Clinical Validation Study BREAKING
NEWS
Read more
Webinar 8 - Multiple Sclerosis (MS) LATEST
VIDEO
More Videos
Frontiers in Medicine On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective Marco Viceconti, Maria Tome, Wilhelmus Dartee, Igor Knezevic, Sabina Hernandez Penna, Claudia Mazzà, Brian Caulfield, Judith Garcia-Aymerich, Clemens Becker, Walter Maetzler, Thierry Troosters, Basil Sharrack, Giorgio Davico, Solange Corriol-Rohou, Lynn Rochester and the Mobilise-D Consortium Other publications LATEST
PUBLICATION
SOCIAL MEDIA Webinar recordings available on our YouTube channel BREAKING
NEWS
Read more
Webinar 8 - Multiple Sclerosis (MS) LATEST
VIDEO
More Videos
Frontiers in Medicine On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective Marco Viceconti, Maria Tome, Wilhelmus Dartee, Igor Knezevic, Sabina Hernandez Penna, Claudia Mazzà, Brian Caulfield, Judith Garcia-Aymerich, Clemens Becker, Walter Maetzler, Thierry Troosters, Basil Sharrack, Giorgio Davico, Solange Corriol-Rohou, Lynn Rochester and the Mobilise-D Consortium Other publications LATEST
PUBLICATION
SOCIAL MEDIA Mobilise-D links with Voice Global to promote global patient engagement BREAKING
NEWS
Read more
Webinar 8 - Multiple Sclerosis (MS) LATEST
VIDEO
More Videos
Frontiers in Medicine On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective Marco Viceconti, Maria Tome, Wilhelmus Dartee, Igor Knezevic, Sabina Hernandez Penna, Claudia Mazzà, Brian Caulfield, Judith Garcia-Aymerich, Clemens Becker, Walter Maetzler, Thierry Troosters, Basil Sharrack, Giorgio Davico, Solange Corriol-Rohou, Lynn Rochester and the Mobilise-D Consortium Other publications LATEST
PUBLICATION
SOCIAL MEDIA

Connecting digital mobility assessment to clinical outcomes
for regulatory and clinical endorsement

What?

What?

Mobilise-D is a 5-year, IMI-funded project that will produce validated and accepted digital mobility outcomes to monitor daily life gait of people with different mobility problems, with the goal to improve follow-up and personalized care.

How?

How?

Mobilise-D will perform a technical and clinical validation of a sensor-algorithm pair in different patient groups. We maintain close dialogue with the European Medicines Agency (EMA) to facilitate the process of regulatory approval.

Who?

Who?

The Mobilise-D consortium consists of 34 partners from Europe and the USA. Over 200 professionals with technical, clinical, and regulatory expertise will work together to bring digital mobility outcomes to the clinic.                                                                  

Mobility – how well we walk – is an important marker of health; a slow walking speed is associated with greater mortality, morbidity, cognitive decline, dementia, and fall risk. As the population ages, the number of people experiencing mobility challenges is expected to rise. However, accurately assessing people’s mobility, especially in the real daily life world, is far from easy.

Mobilise-D will develop a comprehensive system to monitor and evaluate people’s gait based on digital technologies, including sensors worn on the body. The project focuses on conditions which often affect mobility, namely chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure.

The Mobilise-D results will help to improve the accurate assessment of daily life mobility in clinical trials and patient treatment, thereby contributing to improved and more personalised care.

Patient Groups

Mobilise-D will focus on five different patient groups that together represent respiratory problems (chronic obstructive pulmonary disease – COPD), neurodegenerative conditions (Parkinson’s disease – PD), neuroinflammatory problems (multiple sclerosis – MS), osteoporosis and sarcopenia (hip fracture recovery/proximal femoral fracture – PFF), and cardiac pathology (congestive heart failure – CHF).

These patient groups cover a range of walking speed, mobility challenges, and potential events that we care about, such as improving versus worsening of function, falls, hospitalisation, nursing home admission, and death. Furthermore, these patient groups will be followed at 12 different sites across Europe, ensuring a good geographical representation and covering a diverse representation of health care organisation, such as in- versus outpatient care, as well as public versus private health services.

Read More

Twitter Feed


📢Mobilise-D Webinar: Parkinson's Disease📢

Just a few days until our #PD webinar!

📅 Wednesday, October 5
⌚ 16:00 CET
🆓 Free and open to the public

Haven't signed up yet? Register now👇
https://t.co/O9aL7XH6UO https://t.co/0UuT4V7Ik3
Mobilise_D photo

Mobilise-D can only achieve success by working with the people that we aim to benefit. We are working closely with our Patient and Public Advisory Group, and these are some of their main contributions so far⤵✨

🔗 https://t.co/WpDlxxJSYK

#PatientEngagement @IHIEurope @EFPIA https://t.co/gMIQt2ktpz
Mobilise_D photo

Latest News

Mobilise-D and Cure Parkinson’s UK in strategic partnership to accelerate the translation of research into clinical practice

We are excited to announce our strategic partnership with Cure Parkinson’s UK, working closely together to bring our research and clinical studies closer to patients and the public. We asked Helen Matthews, Deputy CEO of Cure Parkinson’s, to share with us her vision about the benefits of the research and clinical trials in Parkinson’s Disease,…

Upcoming Events